AbbVie Inc. Total Assets 2010-2024 | ABBV
AbbVie Inc. total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
- AbbVie Inc. total assets for the quarter ending December 31, 2024 were $135.161B, a 0.33% increase year-over-year.
- AbbVie Inc. total assets for 2024 were $135.161B, a 0.33% increase from 2023.
- AbbVie Inc. total assets for 2023 were $134.711B, a 2.95% decline from 2022.
- AbbVie Inc. total assets for 2022 were $138.805B, a 5.27% decline from 2021.
AbbVie Inc. Annual Total Assets
(Millions of US $) |
| 2024 |
$135,161 |
| 2023 |
$134,711 |
| 2022 |
$138,805 |
| 2021 |
$146,529 |
| 2020 |
$150,565 |
| 2019 |
$89,115 |
| 2018 |
$59,352 |
| 2017 |
$70,786 |
| 2016 |
$66,099 |
| 2015 |
$53,050 |
| 2014 |
$27,513 |
| 2013 |
$29,198 |
| 2012 |
$27,008 |
| 2011 |
$19,521 |
| 2010 |
$21,135 |
| 2009 |
$0 |
AbbVie Inc. Quarterly Total Assets
(Millions of US $) |
| 2024-12-31 |
$135,161 |
| 2024-09-30 |
$143,422 |
| 2024-06-30 |
$141,937 |
| 2024-03-31 |
$148,874 |
| 2023-12-31 |
$134,711 |
| 2023-09-30 |
$136,221 |
| 2023-06-30 |
$135,367 |
| 2023-03-31 |
$134,544 |
| 2022-12-31 |
$138,805 |
| 2022-09-30 |
$141,325 |
| 2022-06-30 |
$143,186 |
| 2022-03-31 |
$143,211 |
| 2021-12-31 |
$146,529 |
| 2021-09-30 |
$148,858 |
| 2021-06-30 |
$147,972 |
| 2021-03-31 |
$150,501 |
| 2020-12-31 |
$150,565 |
| 2020-09-30 |
$149,621 |
| 2020-06-30 |
$149,530 |
| 2020-03-31 |
$91,199 |
| 2019-12-31 |
$89,115 |
| 2019-09-30 |
$59,441 |
| 2019-06-30 |
$57,142 |
| 2019-03-31 |
$56,769 |
| 2018-12-31 |
$59,352 |
| 2018-09-30 |
$66,164 |
| 2018-06-30 |
$61,641 |
| 2018-03-31 |
$69,342 |
| 2017-12-31 |
$70,786 |
| 2017-09-30 |
$68,840 |
| 2017-06-30 |
$66,994 |
| 2017-03-31 |
$65,664 |
| 2016-12-31 |
$66,099 |
| 2016-09-30 |
$66,626 |
| 2016-06-30 |
$67,211 |
| 2016-03-31 |
$53,720 |
| 2015-12-31 |
$53,050 |
| 2015-09-30 |
$54,832 |
| 2015-06-30 |
$53,855 |
| 2015-03-31 |
$26,699 |
| 2014-12-31 |
$27,513 |
| 2014-09-30 |
$28,454 |
| 2014-06-30 |
$29,045 |
| 2014-03-31 |
$28,657 |
| 2013-12-31 |
$29,198 |
| 2013-09-30 |
$28,252 |
| 2013-06-30 |
$27,910 |
| 2013-03-31 |
$27,169 |
| 2012-12-31 |
$27,008 |
| 2012-09-30 |
$22,730 |
| 2012-06-30 |
$17,710 |
| 2012-03-31 |
$18,962 |
| 2011-12-31 |
$19,521 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$21,135 |
| 2009-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$356.743B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
